ASX · ICR.AX
Intelicare Holdings Limited
A$0.02A$0.00 (0.0%)
Intelicare Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 37.5% below the high.
Loading market information…
ASX · IVX.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 03:15 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Invion Limited’s quoted price sits in the lower half of its reported 52-week range, 68.18% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Invion Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma. The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments. Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers. The firm was established in 2000 and is headquartered in Melbourne, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.02A$0.00 (0.0%)
Intelicare Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 37.5% below the high.
A$0.03A$0.00 (0.0%)
InhaleRx Limited’s quoted price sits in the lower half of its reported 52-week range, 41.67% below the high.
A$0.01-A$0.00 (0.0%)
Acrux Limited’s quoted price sits in the lower half of its reported 52-week range, 52.38% below the high.
A$0.08-A$0.00 (-5.06%)
Vectus Biosystems Limited’s quoted price sits in the lower half of its reported 52-week range, 83.52% below the high.
A$0.01+A$0.00 (+7.69%)
Bio-Gene Technology Limited’s quoted price sits in the lower half of its reported 52-week range, 71.43% below the high.
A$0.01-A$0.00 (0.0%)
Cann Group Limited’s quoted price sits in the lower half of its reported 52-week range, 61.54% below the high.
A$0.00-A$0.00 (-25.0%)
HITIQ Limited’s quoted price sits in the lower half of its reported 52-week range, 92.5% below the high.
A$0.00+A$0.00 (0.0%)
Percheron Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 70.0% below the high.
